Table 2.
Baseline characteristics of patients with primary pulmonary synovial sarcoma (PPSS) in the Surveillance, Epidemiology, and End Results (SEER) Database
| Variables (n = 121) | Result |
|---|---|
| Age at diagnosis (y) | |
| Mean ± SD | 50.7 ± 18.2 |
| Median (range) | 50 (12-82) |
| Sex | |
| Female | 57 (47.1) |
| Male | 64 (52.9) |
| Race/ethnicity | |
| Caucasian | 104 (86.0) |
| Non-Caucasian | 17 (14.0) |
| Histologic subtype | |
| Synovial sarcoma, not otherwise specified | 66 (54.5) |
| Spindle cell | 44 (36.4) |
| Epithelioid cell | 1 (0.8) |
| Biphasic | 10 (8.3) |
| Tumor grade, n = 51 | |
| Ⅰ | 2 (1.7) |
| Ⅱ | 5 (4.1) |
| Ⅲ | 27 (22.3) |
| Ⅳ | 17 (14.0) |
| Unknown | 70 (57.9) |
| Laterality | |
| Left | 55 (45.5) |
| Right | 66 (54.5) |
| Primary site | |
| Upper lobe | 49 (40.5) |
| Middle lobe | 7 (5.8) |
| Lower lobe | 46 (38.0) |
| Involving more than 1 lobe | 6 (5.0) |
| Lung, not specified | 13 (10.7) |
| AJCC stage, n = 93 | |
| Ⅰ | 38 (31.4) |
| Ⅱ | 4 (3.3) |
| Ⅲ | 10 (8.3) |
| Ⅳ | 41 (33.9) |
| Unknown | 28 (23.1) |
| Surgery performed, n = 118 | |
| Yes | 89 (73.6) |
| No | 29 (24.0) |
| Unknown | 3 (2.5) |
| Radiotherapy, n = 99 | |
| Yes | 34 (28.1) |
| No | 65 (53.7) |
| Unknown | 22 (18.2) |
| Treatment modality, n = 97 | |
| Surgery with radiotherapy | 25 (20.7) |
| Surgery only | 64 (52.8) |
| Radiotherapy | 7 (5.8) |
| No therapy | 1 (0.8) |
| Unknown | 24 (19.8) |
| Tumor size (cm), n = 102 | |
| Mean ± SD | 9.0 ± 4.9 |
| Median | 8.1 |
| >5 | 77 |
| ≤5 | 25 |
| Unknown | 19 |
| LN involvement, n = 107 | |
| Positive | 12 (9.9) |
| Negative | 95 (78.5) |
| Unknown | 14 (11.6) |
| Distant metastasis, n = 100 | |
| Yes | 41 (33.9) |
| No | 59 (48.8) |
| Unknown | 21 (17.4) |
| Met at bone, n = 60 | |
| Yes | 3 (2.5) |
| No | 57 (47.1) |
| Unknown | 61 (50.4) |
| Met at brain, n = 60 | |
| Yes | 2 (1.7) |
| No | 58 (47.9) |
| Unknown | 61 (50.4) |
| Met at lung, n = 59 | |
| Yes | 2 (1.7) |
| No | 57 (47.1) |
| Unknown | 62 (51.2) |
| Met at liver, n = 60 | |
| Yes | 0 |
| No | 60 (49.6) |
| Unknown | 61 (50.4) |
| Median survival time (mo), n = 121 | 17 |
Values are presented as n (%) unless otherwise noted. AJCC, American Joint Committee on Cancer; LN, lymph node; Met, metastasis.